-PTI German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week. Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company’s decision to cut the price of the life-extending kidney and liver cancer drug “is a clear...

-The Telegraph An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world's latest drug against malaria, an alternative to standard anti-malarial therapy. India’s Ranbaxy Laboratories today launched the new drug for the treatment of uncomplicated malaria caused by the Plasmodium falciparum parasite, after nine years of research which was partly supported by the Indian government. Clinical trials in India, Tanzania, and Thailand...

-PTI Competition watchdog CCI has imposed Rs 317 crore in penalties on three companies, including agro-chemicals major United Phosphorus, for collusive bidding to supply ALP Tablets to Food Corporation of India (FCI).  The aluminium phosphide (ALP) tablet manufacturers -- United Phosphorus, Excel Crop Care, and Sandhya Organics -- have been fined 9 per cent of the their three years' average profits.  ALP Tablets are used by the FCI for preserving its central pool...

That this is the first time a compulsory licence has been granted in India is in itself important. INDIA'S long struggle to ensure access to affordable medicines for its people recently took a positive and interesting turn. In early March, just before he demitted office, Controller General of Patents P.H. Kurian passed an order on an application filed by Natco Pharma, headquartered in Hyderabad, requesting a licence to produce an anti-cancer...

The ICDS' plight is symptomatic of the problems plaguing the Union government's flagship schemes for the poor all over the country.   INDIA may be the only country in the world where we describe the ensuring of the basic socio-economic rights of the people in terms of “flagship schemes” that are seen as the benevolent contribution of governments. One problem with this approach is that the delivery of basic services is...